Do tumor necrosis factor inhibitors cause malformations in humans?

Journal of Rheumatology

Volumn 36, Issue 3, 2009, Pages 465-466

  Koren, Gideon ^a   Inoue, Miho ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

CAUSAL ATTRIBUTION; CENTRAL NERVOUS SYSTEM MALFORMATION; CONGENITAL MALFORMATION; DATA BASE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART VENTRICLE SEPTUM DEFECT; HUMAN; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; TERATOGENESIS; DRUG ANTAGONISM; FEMALE; NOTE; PREGNANCY; PRENATAL EXPOSURE; REGISTER; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 65649114392     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081083     Document Type: Editorial

References (12)

1. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128-1137 (Pubitemid 28227484)
2. Rosa FW. Teratogenicity of isotretinoin. Lancet 1983;2:513.
3. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of TNF antagonists during pregnancy: a review of the FDA database. J Rheumatol 2009;36:635-641
4. Bar-Oz B, Moretti ME, Mareels G, Van Tittelboom T, Koren G. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet 1999;354:1700-1701 (Pubitemid 29533065)
5. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2005;352:2759.
6. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005;73:888-896 (Pubitemid 41742199)
7. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007;64:496-509. (Pubitemid 47404298)
8. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: Effects on fetal and neonatal outcomes. Reprod Toxicol 2008;26:175-177
9. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1990;163:695. (Pubitemid 20287692)
10. Pole M, Einarson A, Pairaudeau N, Einarson T, Koren G. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. J Clin Pharmacol 2000;40:573-577
11. Einarson A, Schachtschneider AK, Halil R, Bollano E, Koren G. SSRI's and other antidepressant use during pregnancy and potential neonatal adverse effects: impact of a public health advisory and subsequent reports in the news media. BMC Pregnancy Childbirth 2005;5:11. (Pubitemid 41460687)
12. Koren G. Medical safety in pregnancy and breastfeeding. New York: McGraw Hill; 2007.